IndiaNifty 5023,398.10▼ -0.34%
IndiaBSE Sensex74,781.76▼ -0.16%
IndiaNifty Bank56,606.55▲ +0.24%
IndiaNifty IT28,921.50▲ +0.11%
IndiaNifty Auto27,304.50▲ 0.00%
IndiaNifty Pharma26,532.40▼ -0.09%
IndiaNifty FMCG45,053.75▲ 0.00%
USS&P 5007,656.98▲ +0.86%
USDow Jones52,573.29▲ +0.98%
USNASDAQ26,333.04▲ +0.96%
UKFTSE 10010,650.40▲ +0.39%
JapanNikkei 22564,011.34▼ -1.93%
Hong KongHang Seng24,805.63▼ -0.60%
GermanyDAX25,568.56▲ +0.82%
FranceCAC 408,179.77▲ +0.78%
AustraliaASX 2008,741.20▼ -0.89%
IndiaNifty 5023,398.10▼ -0.34%
IndiaBSE Sensex74,781.76▼ -0.16%
IndiaNifty Bank56,606.55▲ +0.24%
IndiaNifty IT28,921.50▲ +0.11%
IndiaNifty Auto27,304.50▲ 0.00%
IndiaNifty Pharma26,532.40▼ -0.09%
IndiaNifty FMCG45,053.75▲ 0.00%
USS&P 5007,656.98▲ +0.86%
USDow Jones52,573.29▲ +0.98%
USNASDAQ26,333.04▲ +0.96%
UKFTSE 10010,650.40▲ +0.39%
JapanNikkei 22564,011.34▼ -1.93%
Hong KongHang Seng24,805.63▼ -0.60%
GermanyDAX25,568.56▲ +0.82%
FranceCAC 408,179.77▲ +0.78%
AustraliaASX 2008,741.20▼ -0.89%
Invest and Educate
NYQ · USD

Danaher Corporation

DHR
200.14
▼ -0.39 (-0.19%)
Price Chart
6MO · Daily
2026-03-192026-04-172026-05-152026-06-152026-07-152026-08-122026-09-11161.91176.91191.91206.91218.85
Key Ratios & Fundamentals
Market Cap
148.62B
P/E (TTM)
37.62
Fwd P/E
22.74
P/B
2.83
P/S
5.92
Book Value
74.81
EPS (TTM)
5.62
Fwd EPS
9.30
Div Yield
+0.74%
Beta
0.80
ROE
+7.61%
ROA
+3.95%
D/E
52.97
Current Ratio
1.65
Profit Margin
+15.95%
Op Margin
+19.78%
52W High
242.80
52W Low
160.93
50D Avg
199.70
200D Avg
203.06
Avg Volume
4.73M
Shares Out
702.99M
Sector
Healthcare
Industry
Diagnostics & Research
About Danaher Corporation

Danaher Corporation designs, manufactures, and markets professional, medical, research, and industrial products and services in the United States, China, and internationally. The company operates through Biotechnology, Life Sciences, and Diagnostics segments. The Biotechnology segment provides technologies, consumables, services, and solutions that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, and aseptic fill finish; single-use hardware, consumables, and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services for diagnostic and assay development; and healthcare filtration solutions. The Life Sciences segment provides mass spectrometers; bioanalytical measurement systems; flow cytometry, genomics, lab automation, centrifugation, liquid handling automation instruments, antibodies and reagents, and particle counting and characterization; genome sample preparation; microscopes; protein consumables; filtration products; and genomic medicines, such as custom nucleic acid products, and plasmid DNA, RNA, and proteins under the ABCAM, ALDEVRON, BECKMAN COULTER, GENEDATA, IDT, LEICA MICROSYSTEMS, MOLECULAR DEVICES, PALL, PHENOMENEX, and SCIEX brands. The Diagnostics segment offers clinical instruments, consumables, software, and services that hospitals, physicians' offices, reference laboratories and other critical care settings use to diagnose disease and make treatment decisions. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was incorporated in 1969 and is headquartered in Washington, the District Of Columbia.

SWOT Analysis
Auto-derived from fundamentals
Strengths
  • Healthy net profit margin of 15.9%
  • Strong liquidity (Current Ratio 1.65) — well-covered short-term obligations
  • Large-cap scale — index inclusion, institutional coverage, deep liquidity
Weaknesses
  • Modest ROE of 7.6% — capital efficiency lags peers
Opportunities
  • Rapid earnings growth of 59.7% — operating leverage kicking in
  • Forward P/E of 22.7x is below trailing — market expects earnings growth
  • Positioned in Healthcare — defensive sector, aligned with respective macro cycles
Threats
  • Standard market risks apply — macro cycles, regulatory changes, and competition
Latest News · Danaher Corporation
10 stories
3 Reasons DHR is Risky and 1 Stock to Buy Instead
Danaher currently trades at $204.89 per share and has shown little upside over the past six months, posting a middling return of 5%. The stock also fell short of the S&P 500’s 13.1% gain during that period.
StockStory·1d ago
Thermo Fisher, Danaher Could Log Mid-Single-Digit Organic Revenue Growth in 2027, UBS Says
Thermo Fisher Scientific (TMO) and Danaher (DHR) are likely to return to mid-single-digit organic re
MT Newswires·2d ago
ILMN Stock Keeps Climbing. Should You Climb On?
A gene sequencing leader is on a powerful run fueled by real business quality, forcing investors to decide if the engine has more power than the price tag already reflects.
Trefis·3d ago
Is Revvity Stock a Buy as Growth Improves but Valuation Stays Rich?
Revvity's raised 2026 outlook, Diagnostics growth and stronger cash flow brighten the setup, but premium valuation and software risks call for selectivity.
Zacks·4 Sept 2026
Pediatrix Medical Group (MD) Up 3.4% Since Last Earnings Report: Can It Continue?
Pediatrix Medical Group (MD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks·3 Sept 2026
Danaher (DHR) Seen Deftly Navigating AI Integration
Eagle Capital Management, an investment management company, released its second quarter 2026 investor letter. A copy of the letter can be downloaded here. In the quarter, Eagle Capital Management discussed how enthusiasm around AI capital spending has driven strong S&P 500 earnin
Insider Monkey·3 Sept 2026
Danaher (DHR) Stock Trades Near Fair Value But At An Earnings Premium
Danaher stock has delivered a decline of 26.6% over the past 5 years, yet current checks suggest the shares now trade near an intrinsic value estimate while still screening expensive on traditional multiples. The result is a company with mixed long term performance and a low over
Simply Wall St.·3 Sept 2026
Merck KGaA shares rise 1.7% after HSBC upgrades stock to Buy
Merck KGaA (NYSE:MRK) shares rose 1. 7% to €141.
InvestorsHub·1 Sept 2026
Is Danaher Stock Underperforming the Nasdaq?
Danaher has underperformed the Nasdaq over the past year, but analysts are highly optimistic about the stock’s prospects.
Barchart·31 Aug 2026
Jim Cramer Calls BillionToOne (BLLN) a “Pretty Darn Good Company”
When a caller asked for the Mad Money host’s take on BillionToOne, Inc. (NASDAQ:BLLN) during the lightning round on August 26, Jim Cramer commented: You know, we did a big piece on this, and we decided, you know, it’s a pretty darn good company. I know it’s expensive, but you kno
Insider Monkey·28 Aug 2026
Invest & Educate · Data: Yahoo Finance · News: ET · Mint · Moneycontrol
PrivacyTermsEducational use only. Not investment advice.